Clinical Study Of Duloxetine On Epilepsy Comorbid Depression Disorder

Objective:Depression is the most common psychiatric comorbidity among patients with epilepsy.At present,the diagnosis and treatment of many epilepsy patients still remain in epilepsy itself and ignore the diagnosis and treatment of depression and other mental comorbidities.A large number of clinical studies have proved that duloxetine can be used to treat depression and generalized anxiety disorder.And the latest animal experiments have confirmed that duloxetine hydrochloride has a significant antiepileptic effect by reducing the seizures of epilepsy.Therefore,the purpose of this study is to study the clinical effectiveness and safety of duloxetine hydrochloride for epilepsy and depressive disorders.Method: This study was reviewed by the Medical Science Research Ethics Committee of the First Affiliated Hospital of China Medical University.Patients with epilepsy comorbid depression who were treated in the Department of Psychology or Neurology of the First Affiliated Hospital of China Medical University from January 2019 to January 2020.All patients voluntarily signed informed consent.The enrolled subjects took 60 mg duloxetine enteric-coated capsules(trade name: Xin bai da)daily for 8 weeks.On the day of enrollment,and on the second,fourth,and eighth weeks of the enrollment,subjects must be assessed with relevant scales,including basic information(name,gender,age,education),past history,family history,The type of seizures,the frequency of seizures,the duration of each seizure,the Hamilton Depression Scale(HAMD),the Hamilton Anxiety Scale(HAMA),the Drug Side Effects Scale(TESS),etc.Result: 1.The average scores of Week 2(16.39 points),Week 4(11.78 points)and Week 8(8.50 points)of the HAMD scale are significantly lower than the average score before entry(20.44 points),and There was a statistical difference(p <0.05),indicating that during the second to eighth weeks of taking duloxetine hydrochloride,the patient's depressive symptoms improved significantly.2.The average scores of Week 2(20.72 points),Week 4(15.89 points)and Week 8(10.39 points)of the HAMA scale are significantly lower than the average score before entry(26.22 points),and There was a statistical difference(p <0.05),indicating that the anxiety symptoms of the patient improved significantly from the 2nd to the 8th week of taking duloxetine hydrochloride.3.Compared with before enrollment in the 8th week of treatment,the degree of seizures did not increase significantly,the frequency of seizures decreased significantly,and the duration of each seizure also decreased significantly,indicating that duloxetine hydrochloride has no risk of inducing seizures.Conclusion:Duloxetine is safe and effective for patients with epilepsy and depressive disorders.It can improve the depressive symptoms of patients with epilepsy within the therapeutic dose and has no obvious induction of epilepsy symptoms.t has guiding significance for the treatment of patients with epilepsy comorbid depression in clinical practice.